Iterum Therapeutics plc (NASDAQ:ITRM) saw an upside of 0.08% to $0.53 after subtracting $0.0 on Tuesday. The 5-day average trading volume is 2,680,337 shares of the company’s common stock. It has gained $0.5600 in the past week. An average of 6,026,324 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 4,321,538.
ITRM’s 1-month performance is -17.88% or -$0.1192 on its low of $0.5111 reached on 10/06/21. The company’s shares have touched a 52-week low of $0.45 and high of $2.99, with the stock’s rally to the 52-week high happening on 02/11/21. YTD, ITRM has lost -46.13% or -$0.4594. However, the current price is down -82.20%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Feb 12, 242 days have gone by since the last insider trading activity for Iterum Therapeutics plc (ITRM). DENNER ALEXANDER J (10% Owner) most recently sold 10,619,949 shares at $2.27 per share on Feb 12. This transaction cost the insider $24,107,284. 10% Owner, DENNER ALEXANDER J, sold 10,000,000 shares at a price of $2.59 on Feb 11. Then, on Jan 26, President & CEO Fishman Corey N. sold 85,445 shares at a price of $1.73 per share. This transaction amounted to $147,820.
Iterum Therapeutics plc (ITRM) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.ITRM stock has a beta of 1.27. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 2.05.
Iterum Therapeutics plc’s quick ratio for the period ended June 29 was 2.80, with the current ratio over the same period at 2.80 meaning that ITRM stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.44, while the total debt to equity was 0.54.
For the quarterly period ending June 29 this year, Iterum Therapeutics plc’s cash and short-term investments amounted to $54.87 million against total debt of $30.17 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected ITRM to announce -$0.06 per share in earnings in its latest quarter, but it posted $0.04, representing a 166.70% surprise. EBITDA for the quarter stood at more than -$6.16 million. ITRM stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 58.85 million, with total debt at $30.17 million. Shareholders hold equity totaling $182.78 million
Let’s look briefly at Iterum Therapeutics plc (ITRM) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 39.11% to suggest the stock is trending Neutral, with historical volatility in this time period at 74.38%.
The stock’s 5-day moving average is $0.5289, reflecting a -1.19% or -$0.0064 change from its current price. ITRM is currently trading -11.81% above its 20-day SMA, -53.13% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -34.78% and -47.56% respectively.
Stochastic %K and %D was 12.82% and 12.27% and the average true range (ATR) pointed at 0.0401. The RSI (14) points at 38.29%, while the 14-day stochastic is at 11.74% with the period’s ATR at 0.0437. The stock’s 9-day MACD Oscillator is pointing at -0.0132 and -0.0197 on the 14-day charts.
In the most recent analyst report for Iterum Therapeutics plc (NASDAQ: ITRM), Gabelli & Co upgraded it to a Hold rating. They previously had a Sell rating on the stock. Analysts offering their rating for ITRM stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate ITRM as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.
What is ITRM’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $1.00 and a high of $1.00, with their median price target at $1.00. Looking at these predictions, the average price target given by analysts is for Iterum Therapeutics plc (ITRM) stock is $1.00.